Now showing items 1-3 of 3
Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes
(Springer-Verlag, 2005-11)
Prostate cancer remains a significant health concern for men in the USA as it is a leading cancer diagnosis and a cause of death. With the use of prostate-specific antigen or screening, a stage migration has occurred with ...
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)
(Kluwer Academic Publishers; Springer Science+Business Media, 2005-01)
JM-216 is an orally bioavailable platinum compound with activity against many tumor models. The objective of this study was to determine the safety profile and anti-tumor activity of JM-216 in patients with hormone refractory ...
Phase II trial of fenretinide in advanced renal carcinoma
(Kluwer Academic Publishers; Springer Science + Business Media, Inc., 2005-01)
Purpose : Fenretinide, a synthetic form of retinoid, induced apoptosis even in chemotherapy resistant cell lines. A phase II study was hence conducted to evaluate toxicity and efficacy of fenretinide in metastatic renal ...